Principal Investigator - Dr. Scott Dryden-Peterson MD, MSc
Aim 1: The study will compare the LVEF between patients with and without HIV who are being treated with anthracyclines. We hypothesize that the LVEF will be lower after anthracycline among individuals living with HIV.
Aim 2: In a mechanistic study, we will compare the increase in myocardial fibrosis after anthracyclines between individuals living with HIV and uninfected controls. We hypothesize that that HIV status will be associated with a greater increase in fibrosis after anthracyclines.
The study is a prospective observational cohort study where study subjects will undergo a cardiac magnetic resonance (CMR) study at baseline prior to chemotherapy and at 12 months after chemotherapy.
Study population: Total sample size is 25. These will be recruited from Botswana Prospective Cancer Cohort in Gaborone. This includes the Princess Marina Hospital, Bokamoso Private Hospital, and Gaborone Private Hospital.
- Adults (≥18 years of age) scheduled to start anthracycline-based chemotherapy
Study duration: 5 years
Sponsor: National Institutes of Health- National Cancer Institute (HIH-NCI).